Identification of site-specific prognostic biomarkers in patients with oral squamous cell carcinoma

Neoplasma ◽  
2011 ◽  
Vol 58 (3) ◽  
pp. 217-226 ◽  
Author(s):  
T. TRIVEDI ◽  
R. TANKSHALI ◽  
J. GOSWAMI ◽  
S. SHUKLA ◽  
P. SHAH ◽  
...  
2018 ◽  
Vol 48 (1) ◽  
pp. 31-35 ◽  
Author(s):  
Fereshteh Baghaei ◽  
Alireza Abdollahi ◽  
Hadiseh Mohammadpour ◽  
Mahsa Jahanbin ◽  
Fatemeh Naseri Taheri ◽  
...  

Oral Oncology ◽  
2017 ◽  
Vol 72 ◽  
pp. 38-47 ◽  
Author(s):  
César Rivera ◽  
Ana Karina Oliveira ◽  
Rute Alves Pereira Costa ◽  
Tatiane De Rossi ◽  
Adriana Franco Paes Leme

Hereditas ◽  
2021 ◽  
Vol 158 (1) ◽  
Author(s):  
Wanli Yang ◽  
Wei Zhou ◽  
Xinhui Zhao ◽  
Xiaoqian Wang ◽  
Lili Duan ◽  
...  

Abstract Background Oral squamous cell carcinoma (OSCC) is a malignant cancer, the survival rate of patients is disappointing. Therefore, it is necessary to identify the driven-genes and prognostic biomarkers in OSCC. Methods Four Gene Expression Omnibus (GEO) datasets were integratedly analyzed using bioinformatics approaches, including identification of differentially expressed genes (DEGs), GO and KEGG analysis, construction of protein-protein interaction (PPI) network, selection of hub genes, analysis of prognostic information and genetic alterations of hub genes. ONCOMINE, The Cancer Genome Atlas (TCGA) and Human Protein Atlas databases were used to evaluate the expression and prognostic value of hub genes. Tumor immunity was assessed to investigate the functions of hub genes. Finally, Cox regression model was performed to construct a multiple-gene prognostic signature. Results Totally 261 genes were found to be dysregulated. 10 genes were considered to be the hub genes. The Kaplan-Meier analysis showed that upregulated SPP1, FN1, CXCL8, BIRC5, PLAUR, and AURKA were related to poor outcomes in OSCC patients. FOXM1 and TPX2 were considered as the potential immunotherapeutic targets with future clinical significance. Moreover, we constructed a nine-gene signature (TEX101, DSG2, SCG5, ADA, BOC, SCARA5, FST, SOCS1, and STC2), which can be utilized to predict prognosis of OSCC patients effectively. Conclusion These findings may provide new clues for exploring the molecular mechanisms and targeted therapy in OSCC. The hub genes and risk gene signature are helpful to the personalized treatment and prognostic judgement.


Sign in / Sign up

Export Citation Format

Share Document